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bisphosphonates. For this reason knowledge of the pharmacokinetics of the various bisphosphonates is a mandatory precondition for their use in severe renal impairment or dialysis dependence. Bone disease is a frequent finding in severe renal impairment (Kidney Disease: Improving Global Outcomes [KDIGO] stages IV & V). Most forms are subsumed under the terms renal osteopathy or renal osteodystrophy. However, they do not form a homogeneous syndrome but encompass a whole complex of bone changes characterized on the one hand by chronic vitamin D deficiency and reduced 1-α-hydroxylase activity and on the other by secondary hyperparathyroidism (1) . Other critical determinants of bone metabolism include chronic metabolic acidosis, raised ß2-microglobulin levels (2, 3) and regular heparin treatment in dialysis (4) (Fig. 1) . Most current treatments in dialysis patients aim to lower parathyroid hormone (PTH) levels into the guideline range (Kidney Disease Outcome Quality Initiative [KDOQI]) (5) . Additional aims are to lower calcium and phosphate levels into their predefined target ranges. But since this barely influences the critical determinants just mentioned, such therapy often has a limited impact on bone. Approaches aimed at treating bone metabolism directly are only in their infancy and to be viewed in the main as experimental. Nevertheless, patients in stage IV or V chronic renal failure are known to be at above-average fracture risk even after their PTH levels have been lowered into the KDOQI guideline range (Tab. I) (6) . Hence the need to elucidate the feasibility of bisphosphonate use in severe renal impairment or dialysis dependence.
Pharmacokinetics
The only bisphosphonates for which targeted pharmacokinetic studies are available in dialysis-dependent renal failure are clodronate (7, 8) , an early non-aminobisphosphonate, and ibandronate (9) and pamidronate (10) , both among the newer aminobisphosphonates.
abstract
Bisphosphonates have become a standard treatment for osteoporosis and malignant bone disease. Most are contraindicated in severe renal insufficiency because they are eliminated exclusively by the kidneys. However, the marked impairment of bone metabolism in many dialysis patients provides a rationale for their judicious use in this setting. Animal studies reveal that bisphosphonates inhibit hyperparathyroid bone changes. Clodronate, pamidronate and ibandronate are also readily dialyzable, enabling them to be used in dialysis patients. Initial pilot studies in dialysis patients have confirmed the positive effect on hyperparathyroid bone disease observed in animal models. However, large randomized placebocontrolled trials are required before the use of bisphosphonates in renal osteopathy can be generally recommended.
introduction
Bisphosphonates have become a standard treatment for osteoporosis and malignant bone disease. Their mechanism of action − osteoclast inhibition − makes them a valuable treatment option in all forms of bone disease associated with increased osteoclast activity. Since bisphosphonates are either bound to bone or excreted intact via the kidney, there has been reluctance to consider their use in renal impairment. In addition, some bisphosphonates have become notorious for nephrotoxic complications, although this has been confined almost exclusively to their use in malignant bone disease, in particular multiple myeloma. 
Clodronate
Two studies used a similar design to determine the dialyzability of clodronate, infusing 300 mg over two hours prior to four-hour dialysis (7, 8) . Calculated clodronate clearances, 86 ± 10 mL/min and 88 ± 16 mL/min, were largely similar to those for normal renal function. A study of clodronate uptake into bone found a clear dependency on PTH levels and bone metabolism: the higher the PTH, the greater the bone uptake (11) .
Ibandronate
Clearance of ibandronate 1 mg administered at the start of fourhour hemodialysis was 92 ± 19 mL/min, a value likewise virtually identical to that for normal renal function (9) . To quantify bone binding in the absence of subsequent dialysis, ibandronate 2 mg was administered at the end of a dialysis session and bone binding equated with non-renal clearance (12) . Unlike clodronate, ibandronate was 95% to 99% cleared from the circulation (= bound to bone), but independently of PTH or other bone metabolism markers. This naturally carries the risk of the near-total ibandronate dose being taken up in bone, even in low turnover bone. Appropriate caution is thus recommended in therapy.
Pamidronate
Clearance of 1 mg radiolabeled pamidronate was 69 ± 17 mL/min (10) . No bone-binding data are available for pamidronate in dialysis patients. Thus, all bisphosphonates studied to date have proven to be readily dialyzable: four-hour dialysis clears 35% to 40% of the administered dose (Tab. II), which is approximately equivalent to renal bisphosphonate elimination in normal renal function. In the case of pamidronate, however, there is some uncertainty as to whether the clearance of 1 mg is extrapolable to a standard clinical dose of 60-90 mg. With the other bisphosphonates the doses were in each case relatively close to those in clinical use.
Continuous ambulatory peritoneal dialysis (CAPD)
Because bone metabolism in CAPD has only been studied with methylene-bisphosphonate (13) , no figures for bisphosphonate clearance via CAPD can be provided.
Animal studies
Initial models of bisphosphonate therapy for hyperparathyroid bone disease were explored in animals using ibandronate (14) , olpadronate (15) , and pamidronate (16) . Ibandronate 1.25 µg/kg or placebo was administered subcutaneously (sc) weekly for three weeks to 2/3 nephrectomized rats and the results compared with sham-operated controls with normal renal function (14) . Ibandronate com- pletely abolished the bone effects of developing hyperparathyroidism in nephrectomized rats. Bone resorption parameters (deoxypyridinoline) and bone volume to total volume (BV/TV) in the ibandronate group were almost identical to those in the rats with normal renal function. A near-identical study design in 5/6 nephrectomized rats administered olpadronate 1.6 µg sc weekly for five weeks found a similar effect (15) . After an initial increase in deoxypyridinoline in nephrectomized animals, levels in the active treatment group subsequently declined to those in the sham-operated animals versus marked bone resorption in the placebo controls. Olpadronate significantly reduced the tartrate-resistant acid phosphatase (TRAP) positive osteoclast count and significantly increased bone volume.
In the pamidronate study, rats were 5/6 nephrectomized, uninephrectomized, or left intact; 14 weeks later, the uni and 5/6 nephrectomized rats received pamidronate 3 mg/kg/ week sc or placebo for eight weeks; the intact rats received placebo (16) . Whereas the uninephrectomized rats developed only mild renal failure with no marked bone metabolic effects, PTH values increased 5-fold in the 5/6 nephrectomized rats. Bone histology revealed renal osteopathy with osteitis fibrosa and increased bone turnover. Pamidronate therapy markedly decreased bone metabolism in all animals and attained values below the normal range, while bone density increased significantly. However, no animal developed osteomalacia.
clinical studies (tab. iii)
The use of bisphosphonates for hyperparathyroid bone disease in dialysis patients has been the subject of varied editorials for years. The available animal studies indicate that such an approach is highly promising. All the more astonishing, therefore, that there should still be virtually no data on the use of the various bisphosphonates in this setting. The first trial of clodronate in dialysis patients dates from 1990 (17). However, this was a very brief study in nine patients with severe hyperparathyroid bone disease who received an infusion of clodronate 300-600 mg at the end of five consecutive dialysis sessions. A significant fall was observed in bone resorption parameters (hydroxyproline) and calcium and phosphate levels. Alkaline phosphatase (AP) and PTH values, on the other hand, increased. While some of the patients were simply followed up, others received clodronate 1.6 g orally daily for a further two weeks. Only these longertreated patients showed sustained benefit in terms of their laboratory parameters. In a longer, 12-month, open-label and non-placebo-controlled study, 13 patients with persistent severe hyperparathyroidism (PTH >500 pg/mL [normal 12-65 pg/mL]), hypercalcemia (>11 mg/dL), normal phosphate, and osteopenia (T-score <1 SD), received an infusion of pamidronate 60 mg every two months during dialysis (18) . Bone density increased significantly in both the lumbar spine and femoral neck. PTH levels were massively increased at three months, however, only to reverse subsequently in ten of the 13 patients: by one year, PTH levels in these 10 patients had fallen significantly below baseline, while the calcitriol dose had been increased from 1 µg/week to 3 µg/week without causing the hypercalcemia that had previously made such an increase impossible. Whether the PTH-lowering effect was directly because of the pamidronate or the increased dose of calcitriol remains an open question. In another open-label study with no placebo arm, 16 patients with T-score ≤1.0 SD, PTH ≥2 × normal, and no reduction in other bone metabolism parameters (TRAP5b, bone-specific AP and CrossLaps) received an injection of ibandronate 2 mg after dialysis every four weeks for 1 year; 11 patients were eventually fit for assessment (19 Significantly increased bone density in lumbar spine BAP = bone-specific alkaline phosphatase; PTH = parathyroid hormone; TRAP5b = tartrate-resistant acid phosphatase 5b.
nificant increase in the primary endpoint, lumbar spine bone density. At three months, as in the two studies above, PTH levels were markedly increased. However, as in the pamidronate study, they had fallen below baseline by the end of the study. Unlike in the pamidronate study, PTH levels remained within the KDOQI guideline range (5) throughout the study. Bone metabolism markers, except for CrossLaps, showed only a slight non-significant fall. Calcitriol doses underwent a slight but non-significant increase during the study. The only placebo-controlled study of bisphosphonates in the treatment of renal osteopathy was performed with oral alendronate 40 mg/week for six weeks in 31 dialysis patients over 40 years of age with PTH levels between 100 and 300 pg/mL (20) . Hip and lumbar spine densities were measured at baseline and six months, and osteocalcin, PTH, calcium, phosphorus and AP at baseline, one, three, and six months. Here again PTH levels increased on bisphosphonate therapy. Hip density remained stable in the alendronate group while decreasing significantly in the placebo group. The other parameters did not differ between the groups.
discussion
All studies to date have shown the bisphosphonates to be readily dialyzable. Despite higher protein binding in some cases, bisphosphonate clearance during a fourhour dialysis session is consistently equivalent to that for normal renal function. Thus, a single dialysis session can largely clear a dose of bisphosphonate. For this reason, if the aim is not to lose much of the dose immediately, bisphosphonates should be administered after dialysis. To date, binding to bone in dialysis patients has only been studied for clodronate and ibandronate. The results revealed a marked difference between the aliphatic first-generation bisphosphonate clodronate and the aminobisphosphonate ibandronate. Ibandronate showed a very high affinity for bone independently of bone metabolism, whereas with clodronate there was a close correlation with bone turnover. This carries the great danger that the near totality of the ibandronate dose binds to bone even if bone metabolism is already low.
Several animal studies have clearly shown that bisphosphonate therapy reverses both the histologic changes of experimental hyperparathyroidism and the changes in bone metabolism parameters. Osteomalacia was not induced despite the substantial reduction in bone remodeling. Bone density increased markedly, as in the osteoporosis studies. yet despite these pharmacokinetic findings and experimental renal osteopathy results, clinical study data are meager: just three studies in small numbers of dialysis patients receiving bisphosphonates. Doubtless all three studies have substantial weaknesses here and there and are no substitute for large randomized placebo-controlled clinical trials, but they do point to a trend. In terms of weaknesses, none of the studies incorporated the gold standard investigation for diagnosing high turnover osteopathy, namely bone biopsy, and all patient numbers were very low. The studies also relied on bone density and surrogate markers of bone metabolism (21), not the fracture rates used in the pivotal studies of bisphosphonates in the treatment of osteoporosis.
In the pamidronate study it is also unclear how much of the drug administered during dialysis was even taken up in bone, since pamidronate is readily dialyzable. The alendronate study can be criticized for the ultralow dose used. Nevertheless, some observations remain that are consistent across all three studies. Thus, bisphosphonates increase or stabilize bone density compared to placebo in dialysis patients too. They also increase PTH levels, according to a study of this phenomenon by Lu et al (22) , because of a transient decrease in calcium. However, PTH levels subsequently fall to below baseline, i.e. the effect is only transient.
Many questions remain open -treatment dose, for a start. It could be argued that the higher bone metabolism than in osteoporosis requires a higher dose of bisphosphonate. On the other hand, the absence of renal excretion means that no bisphosphonate gets lost, with virtually the entire dose being available to bone. Dose-finding studies are clearly needed. It is also uncertain whether low bone density alone, as in osteoporosis, is a sufficient indication for bisphosphonate therapy in dialysis patients (23) (24) (25) . The danger in low-turnover osteopathy is that the bisphosphonate radically inhibits residual bone turnover, resulting in adynamic bone. Since PTH elevation alone does not exclude low-turnover osteopathy (26, 27) , every dialysis patient would ideally need a bone biopsy before commencing bisphosphonate therapy.
Other unresolved questions concern the duration of bisphosphonate therapy in high-turnover osteopathy and the most appropriate parameters for monitoring treatment. Special attention should be given to potential side effects of the bisphosphonates, especially the osteonecrosis of the jaw. This severe side effect is reported mainly in patients with high dose bisphosphonate treatment for malignant bone disease who undergo dental surgery (28) . Only few case reports of ONJ in dialysis patients are reported (29) . Another point of interest might be the dosage of calcitriol, which increased in two studies (18, 19) . Rising PTH levels after starting bisphosphonate treatment lead to a higher dosage of calcitriol with the potential risk of higher calcium and phosphorus levels. On the other hand, several studies demonstrated a calcium and phosphorus lowering effect of bisphosphonate treatment (30) (31) (32) (33) . Therefore, the risk of high calcium and phosphorus levels leading to a diffuse tissue or vascular calcification would be low. In addition, bisphosphonates have also shown a direct beneficial effect on tissue and vascular calcification (34) (35) (36) . A case can be made on the basis of the data presented for extending bisphosphonate therapy to dialysis patients with certain forms of renal osteopathy. However, in the complete absence to date of large randomized placebo-controlled trials, such therapy can only be recommended at best as an individual management decision. In such cases, prior bone biopsy to confirm high-turnover osteopathy is mandatory.
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